Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant radioimmunotherapy plus Stupp regimen in glioblastoma (Phase II)
ChiCTR2600119452Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in glioblastoma (GBM), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 6-month progression-free survival rate (PFS6). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2600119452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119452.